CDC42 and myeloproliferative neoplasm: Overall, these results indicate that heterogeneous JAK–STAT signaling regulates CDC42-dependent HSC polarity and niche interactions in MPN subtypes, leading to differential remodeling of the microenvironment and response to JAK inhibitor (Extended Data Fig. 10c).